Literature DB >> 20486882

European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.

Eric A F Simões1, Xavier Carbonell-Estrany, John R Fullarton, Giovanni A Rossi, Ignazio Barberi, Marcello Lanari.   

Abstract

OBJECTIVES: A model for predicting respiratory syncytial virus hospitalization in infants born 33-35 weeks' gestational age (wGA) has been developed from the Spanish FLIP study risk factors. The model correctly classified 71% of cases and the area under the receiver operating characteristic (ROC) curve was 0.791. To assess its applicability in Italy, the model was validated against data from the Osservatorio VRS study.
METHODS: Discriminant function analysis was used to validate the model by (a) using the predictive variables identified in FLIP to generate a function from the Italian data and (b) applying the coefficients from the FLIP calculations to the Italian data.
RESULTS: The function calculated from the Italian data provided 77% accurate classification (ROC: 0.773). Applying the FLIP coefficients to the Italian data resulted in correctly classifying 68% of cases and a ROC of 0.760. The number needed to treat to prevent hospitalization of 80% of at risk infants was 13.4, based on a hospitalization rate of 5% and 80% treatment efficacy.
CONCLUSIONS: The Italian data confirm the predictive ability of the model, which could be used to target palivizumab prophylaxis in Italian infants born 33-35 wGA.

Entities:  

Mesh:

Year:  2010        PMID: 20486882     DOI: 10.3109/14767058.2010.482610

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  9 in total

1.  A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-01       Impact factor: 3.267

Review 2.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

3.  Risk factors for severe respiratory syncytial virus lower respiratory tract infection.

Authors:  Constanze Sommer; Bernhard Resch; Eric A F Simões
Journal:  Open Microbiol J       Date:  2011-12-30

4.  Burden of Respiratory Syncytial Virus Hospitalizations in Canada.

Authors:  Ian Mitchell; Isabelle Defoy; ElizaBeth Grubb
Journal:  Can Respir J       Date:  2017-11-07       Impact factor: 2.409

5.  Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.

Authors:  B Resch; V S Bramreiter; S Kurath-Koller; T Freidl; B Urlesberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-11       Impact factor: 3.267

6.  Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.

Authors:  Maarten O Blanken; Hendrik Koffijberg; Elisabeth E Nibbelke; Maroeska M Rovers; Louis Bont
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

7.  Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study.

Authors:  Michela Silvestri; Francesca Marando; Anna Maria Costanzo; Umberto di Luzio Paparatti; Giovanni A Rossi
Journal:  Ital J Pediatr       Date:  2016-04-26       Impact factor: 2.638

Review 8.  Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).

Authors:  Lina Bollani; Eugenio Baraldi; Gaetano Chirico; Andrea Dotta; Marcello Lanari; Antonello Del Vecchio; Paolo Manzoni; Antonio Boldrini; Piermichele Paolillo; Sandra Di Fabio; Luigi Orfeo; Mauro Stronati; Costantino Romagnoli
Journal:  Ital J Pediatr       Date:  2015-12-15       Impact factor: 2.638

Review 9.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.

Authors:  Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Louis Bont; Paul A Checchia; Brigitte Fauroux; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-09-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.